BAT2206 is Bio-Thera Solutions’ third EC approvedproduct Guangzhou, China– August , 2024 – Bio-Thera Solutions Inc. (688177:SH), a commercial-stage biopharmaceutical companydeveloping a pipeline of innovative therapies and biosimilars, today announcedthat the EC has approved BAT2206 (ustekinum...
DetailsGuangzhou – July 16, 2025 – Bio-Thera Solutions, Ltd (688177:SH), a commercial-stagebiopharmaceutical company developing a pipeline of biosimilars and innovative todayannounced that the U.S. Food and Drug Administration (FDA) has accepted itsBiologics License Application (BLA) for BAT2506, a pro...
Guangzhou,China – July 2025 – Bio-Thera Solutions, Inc. (688177:SH), a commercial-stagebiopharmaceutical company developing a pipeline of innovative therapies andbiosimilars, today announced that the Independent Data Monitoring Committee(IDMC) has recommended early study termination for the pivo...
Guangzhou, China– June 25, 2025 – Bio-TheraSolutions Inc. (688177:SH), acommercial-stage biopharmaceutical company developing a pipeline of innovativetherapies and biosimilars, today announced that dosing has begun in a phase 3clinical study for BAT8006, an antibody drug conjugate targeting fola...
